1. Introduction {#sec1}
===============

The novel coronavirus disease (COVID-19) was first reported from Wuhan, China, on 31 December 2019 and has been expanding globally with 78,811 confirmed cases \[[@bib1]\]. The cruise ship Diamond Princess took a travel route that originated in Yokohama on 20 January and included stops in Japan (Kagoshima), Hong Kong, Vietnam, Taiwan, and Japan (Okinawa), before returning to Yokohama on 3 February. A passenger who disembarked on 25 January in Hong Kong presented with a cough that had been present since 19 January; the patient was diagnosed as having COVID-19 on 1 February. The Japanese government requested the ship to stay in the port, with no passengers or crew disembarking, when it arrived in Yokohama on 3 February. On 5 February, a laboratory confirmation of a case of COVID-19 led to the quarantine of the Diamond Princess for 14 days beginning at 7 a.m., with passengers requested to stay in their cabins. As of 5 February, there were a total of 3,711 individuals on board the ship, including 2,666 passengers and 1,045 crew members. Among the 3,711 persons on board on 5 February, 301 symptomatic cases and 318 asymptomatic cases were confirmed to have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by polymerase chain reaction (PCR) \[[@bib2]\]. Some of the symptomatic cases were referred to our hospital; we describe the clinical characteristics of the COVID-19 patients here.

2. Methods {#sec2}
==========

We conducted a retrospective observational study of the COVID-19 cases who were admitted to the Yokohama Municipal Citizen\'s Hospital between 5 and 19 February 2020. A case is defined as a person who had a fever or respiratory symptoms occurring within 14 days after staying on the Diamond Princess with SARS-CoV-2 detection by PCR. PCR was performed on pharyngeal swabs, nasopharyngeal swabs, or sputum in the National Institute of Infectious Diseases or regional public health centers using a previously reported method \[[@bib3]\]. Symptomatic resolution was defined as a temperature \<37.5 °C lasting more than 24 h and almost complete resolution of respiratory symptoms. Clinical severity was classified as mild, moderate, severe, or critical according to the National Health Commission of China \[[@bib4]\].

3. Results {#sec3}
==========

There were 17 cases ([Table 1](#tbl1){ref-type="table"} ). The average age was 69 years; 9 were female, 10 were Asian, 7 were Caucasian, and none were from mainland China. The average period from the onset of symptoms to admission was 5.0 days. The average Charlson Comorbidity Index was 0.7. Six patients did not have any chronic diseases, and six had chronic respiratory diseases (chronic obstructive pulmonary disease, bronchial asthma, or interstitial pneumonia). Fever, cough, and sputum were common symptoms, and the maximum temperature in their clinical course was 38.0 °C. Five patients needed oxygen therapy on admission, and another two patients needed oxygen therapy after admission. Blood tests on admission revealed that lymphocyte percent was lower than reference range in 9 cases and the absolute lymphocyte count was 457, 643 and 862/μL in the critical cases. C-reactive protein (CRP) levels were elevated in 11 cases, lactate dehydrogenase (LDH) and creatine kinase (CK) were elevated in 8 cases, and D-dimer was elevated in 7 cases (for 2 cases, blood tests were performed in the former hospitals) ([Table 2](#tbl2){ref-type="table"} ). Chest X-rays showed a bilateral ground-glass shadow in 10 cases, thickened bronchial walls in 1 case, and no abnormal changes in 6 cases. A chest computed tomography (CT) scan was performed in seven cases and showed multiple ground-glass opacities predominantly in the peripheral area ([Fig. 1](#fig1){ref-type="fig"} ). Consolidations were observed in two of the cases that were admitted to the intensive care unit (ICU). Antibiotics were provided in eight cases, antiviral agents (oseltamivir, peramivir or lopinavir/ritonavir) were provided in eight cases, and corticosteroid pulse therapy was provided in two cases ([Table 3](#tbl3){ref-type="table"} ). Oseltamivir, peramivir or lopinavir/ritonavir was given because neuraminidase inhibitors and lopinavir/ritonavir were used in the previous reports and were expected to have some antiviral effects on the SARS-CoV-2 \[[@bib5]\]. Lopinavir/ritonavir was introduced in four severe to critical cases, but it was stopped in two cases because of drug interaction. Six, three, five, and three cases had mild, moderate, severe, and critical illness, respectively. All the critical patients were cared for in the ICU; all of them had chronic diseases. Two of them were on invasive mechanical ventilation, one received high-flow nasal cannula oxygen therapy, and one received continuous renal replacement therapy.Table 1Clinical characteristics of the patients.Table 1CharacteristicValueNumber of cases17Average age ± SD \[years\]69 ± 10Male: female8 : 9Asian: Caucasian10 : 7Residence Japan7 United Sates5 Australia2 Hong Kong2 Taiwan1Comorbidities Hypertension4 Cardiovascular5 Diabetes3 Malignancy0 Cerebrovascular1 Respiratory6 Chronic kidney disease1 Immunosuppresive1Average Charlson Comorbidity Index ± SD0.7 ± 0.92Average period from symptom onset to admission ± SD \[days\]5 ± 4.5Symptoms Cough14 (82%) Fever14 (82%) Sputum9 (53%) Fatigue8 (47%) Sore throat7 (41%) Dyspnea6 (35%) Runny nose5 (29%) Nausea/vomiting4 (24%) Muscle pain2 (12%) Drowsiness2 (12%) Diarrhea1 (6%)Chest X-ray17 Bilateral ground-glass opacities10 (59%) Bronchial wall thickening1 (6%) No abnormality6 (35%)Chest computed tomography7 Bilateral lesions7 (100%) Ground-glass opacities7 (100%) Peripheral dominance6 (86%) Reticular pattern4 (57%) Crazy paving pattern3 (43%) Consolidations2 (9%)Disease severity Mild6 (35%) Moderate3 (18%) Severe5 (29%) Critical3 (18%)Table 2Laboratory findings.Table 2ParameterHigherNormalLowerReference rangeAST (aspartate aminotransferase)51208--38 IU/LALT (alanine aminotransferase)41304--44 IU/LLDH (lactate dehydrogenase)890106--211 IU/LCK (creatine kinase)89033--115 IU/LBUN (blood urea nitrogen)41308--21 mg/dLCRE (creatinine)31400.36--0.9 mg/dLCRP (C-reactive protein)125NA0--0.5 mg/dLPCT (procalcitonin)59NA0--0.05 ng/dLWBC (white blood cells)31133.5--9 × 10^3^/μLLymphocytes08923--48%PLT (platelets)0170130--370 × 10^3^/μLPT-INR (prothrombin time-international normalized ratio)11500.8--1.2D-dimer77NA0--1 μg/mL[^1]Fig. 1Typical chest computed tomography (CT) image. The image of a severe COVID-19 case showed bilateral ground-glass opacities and reticular pattern in the left lower lobe. Both lesions were located predominantly in the periphery of the lung.Fig. 1Table 3Treatments and outcomes.Table 3VariableValueAntibiotics8 Azithromycin6 Ceftriaxone5 Tazobactam/piperacillin3 Meropenem1 Cefmetazole1Antiviral agents8 Oseltamivir5 Peramivir3 Lopinavir/ritonavir4Corticosteroid therapy2Invasive mechanical ventilation2High-flow nasal cannula oxygen therapy1Renal replacement therapy1Extracorporeal membrane oxygenation (ECMO)0Outcomes Symptomatic resolution14 No symptomatic resolution2 Death1Length of disease and polymerase chain reaction (PCR) positivity Length from symptom onset to symptomatic resolution ± SD \[days\] (*n* = 14)7.9 ± 6.0 Length from symptom onset to last PCR positive finding ± SD \[days\] (*n* = 10)14.8 ± 7.4 Length from symptomatic resolution to last PCR positive finding ± SD \[days\] (*n* = 9)6.6 ± 5.5

After the cases had been followed for 16 ± 5.8 days on average, all of the cases, except for the critical cases, reached symptomatic resolution. One of the critical cases resulted in death due to multiple organ failure. The patient was an Asian man in his seventies who had hypertension, cardiovascular disease, cerebrovascular disease, diabetes, and chronic kidney disease. The average period from symptom onset and symptomatic resolution to the last detection of SARS-CoV-2 in respiratory samples was 15 days (minimum 4, maximum 29) and 6.3 days (minimum 0, maximum 17), respectively.

4. Discussion {#sec4}
=============

This is a large case series of a COVID-19 outbreak on the cruise ship. In our cases, the major symptoms were fever and cough, and the frequency of these symptoms was similar to those in previous reports from China \[[@bib5],[@bib6]\]. However, sputum was more frequent in this study (nine cases, 53%). One patient suffered from watery diarrhea for seven days and was referred to our hospital because of dehydration. A bacterial culture, glutamate dehydrogenase antigen, and norovirus antigen from a stool sample were negative, suggesting that diarrhea may be a symptom of COVID-19. Digestive symptoms appeared in 50.5% of COVID-19 cases according to a report \[[@bib7]\], the frequency of diarrhea and nausea/vomiting varied depending on the reports, 2.0--17% and 1.0--10%, respectively \[[@bib5], [@bib6], [@bib7], [@bib8]\]. Additionally, patients with digestive symptoms had a significantly longer time from onset to admission than patients without digestive symptoms (9.0 days vs 7.3 days) \[[@bib7]\].

The laboratory findings were similar to those of previous studies \[[@bib5],[@bib6]\]. On admission, CRP was elevated in 11 cases (65%) and the percentage of lymphocytes was reduced in 9 cases (53%). The absolute lymphocyte number was very low (\<900/μL) in all the critical cases, which was reported to be associated with poor prognosis \[[@bib9]\]. The CRP levels in the critical cases were 20.1, 12.1, and 8.2 mg/dL, which tended to be higher than those in the noncritical cases ([Fig. 2](#fig2){ref-type="fig"} ). We observed only one patient with a CRP level over 8.0 mg/dL (16.2 mg/dL) without ICU admission, and he progressed to severe illness with a maximum 4 L/min of oxygen therapy. CRP was elevated in 82% of the COVID-19 cases in a report from China, but the titer was not described \[[@bib5]\]. A meta-analysis reported that CRP was significantly elevated in severe cases compared to non-severe cases and discussed that the elevation of interleukin 6 (IL-6), serum ferritin and CRP pointed to development of a systemic inflammatory response syndrome (SIRS) picture in patients with a severe form of COVID-19 \[[@bib10]\]. A high level of CRP might be a marker of progression to severe or critical illness.Fig. 2C-reactive protein (CRP) titer according to disease severity. Critical cases tended to have higher levels of CRP on admission than noncritical cases.Fig. 2

Chest images in previous studies showed rapid evolution from focal unilateral to diffuse bilateral ground-glass opacities that progressed to or coexisted with consolidations within 1--3 weeks \[[@bib8]\]. The CT findings from our cases showed bilateral ground-glass opacities, with consolidation in two of the critical cases. These findings are compatible with the images reported from China \[[@bib6],[@bib8]\].

Effective antiviral therapy for COVID-19 has not been established. China has more than 80 current or pending clinical trials of potential treatments for COVID-19 \[[@bib11]\]. We used oseltamivir, peramivir, and lopinavir/ritonavir, but we did not observe any apparent clinical efficacy. A randomized, controlled, open-label trial involving hospitalized severe patients with COVID-19 showed that no benefit was observed with lopinavir--ritonavir treatment beyond standard care \[[@bib12]\]; besides, this therapy might be difficult to introduce in critical cases because of drug interactions.

The crude fatality rate was reported to be 3.8% of 55,924 laboratory-confirmed cases in China \[[@bib13]\]. Mortality is higher among males and increases with age and with comorbid conditions: 13.2% for those with cardiovascular disease, 9.2% for those with diabetes, 8.4% for those with hypertension, and 8.0% for those with chronic respiratory disease. The patient who died in our study was a man in his seventies with multiple comorbidities. The critical cases were admitted to the ICU 5, 7, and 7 days after symptom onset. A previous study reported a median of 10.5 days from symptom onset to ICU admission \[[@bib14]\]. The delay between symptom onset and exacerbation to respiratory failure may be characteristic of this disease. In mice infected with SARS-CoV-2, ealry administration of an antiviral agent improved pulmonary function, and reduced virus titer and body weight loss \[[@bib15]\]. Although promising antiviral therapy has not been developed, to improve the disease outcome we might have to start antiviral therapy as soon as possible.

SARS-CoV-2 was detected by PCR for 7 days after symptomatic resolution. The longest period from symptom onset to the last PCR positive result in respiratory samples in our cases was 29 days after symptomatic resolution. The time from symptom onset to recovery ranged from 12 to 32 days in a previous study \[[@bib16]\]. That study reported that virus was detected again after recovery. We did not perform viral culture in this study and had difficulty in estimating the infectiousness. A study revealed that the virus was readily isolated during the first week of symptoms from a considerable fraction of samples, no isolates were obtained from samples taken after day 8 in spite of ongoing high viral loads \[[@bib17]\]. Therefore, it is unclear whether the virus could be transmitted from patients to healthy people for a long time after symptomatic resolution.

This study has limitations. The number of cases was small and the duration of the study was short. Most cases were elderly, and we may not be describing all of the clinical characteristics of COVID-19 infection.

In conclusion, this study extensively describes the clinical characteristics of COVID-19 cases in an outbreak on the cruise ship Diamond Princess.
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